Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics in inflammatory diseases and immuno-oncology, announces that it has expanded into new premises in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK's leading parks for science and technology companies. Sitryx has developed rapidly since its transformative
Sitryx is an England-based biopharmaceutical company that researches and develops immune cell metabolism therapies for the treatment of chronic autoimmune diseases and cancer.